Technavio has been monitoring the post-traumatic stress disorder therapeutics market and it is poised to grow by USD 909.86 million during 2020-2024, progressing at a CAGR of over 9% during the forecast period. The report offers an up-to-date analysis regarding the current market scenario, latest trends and drivers, and the overall market environment.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200525005262/en/
Technavio has announced its latest market research report titled Global Post-Traumatic Stress Disorder (PTSD) Therapeutics Market 2020-2024 (Graphic: Business Wire)
Technavio suggests three forecast scenarios (optimistic, probable, and pessimistic) considering the impact of COVID-19. Please Request Free Sample Report on COVID-19 Impact
The market is fragmented, and the degree of fragmentation will accelerate during the forecast period. AstraZeneca Plc, Azevan Pharmaceuticals Inc., Bionomics Ltd., Eli Lilly and Co., GlaxoSmithKline Plc, H. Lundbeck AS, Mylan NV, Neurocrine Biosciences Inc., Novartis International AG, and Pfizer Inc. are some of the major market participants. The rising prevalence of PTSD will offer immense growth opportunities. To make the most of the opportunities, market vendors should focus more on the growth prospects in the fast-growing segments, while maintaining their positions in the slow-growing segments.
Rising prevalence of PTSD has been instrumental in driving the growth of the market.
Post-traumatic Stress Disorder Therapeutics Market 2020-2024: Segmentation
Post-traumatic Stress Disorder Therapeutics Market is segmented as below:
- Product
- Antidepressants
- Anxiolytics
- Other PTSD Therapeutics
- Geography
- North America
- APAC
- Europe
- South America
- MEA
To learn more about the global trends impacting the future of market research, download a free sample: https://www.technavio.com/talk-to-us?report=IRTNTR40905
Post-traumatic Stress Disorder Therapeutics Market 2020-2024: Scope
Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources. Our post-traumatic stress disorder therapeutics market report covers the following areas:
- Post-traumatic Stress Disorder Therapeutics Market size
- Post-traumatic Stress Disorder Therapeutics Market trends
- Post-traumatic Stress Disorder Therapeutics Market industry analysis
This study identifies emerging therapies for PTSD treatment as one of the prime reasons driving the post-traumatic stress disorder therapeutics market growth during the next few years.
Post-traumatic Stress Disorder Therapeutics Market 2020-2024: Vendor Analysis
We provide a detailed analysis of vendors operating in the post-traumatic stress disorder therapeutics market, including some of the vendors such as AstraZeneca Plc, Azevan Pharmaceuticals Inc., Bionomics Ltd., Eli Lilly and Co., GlaxoSmithKline Plc, H. Lundbeck AS, Mylan NV, Neurocrine Biosciences Inc., Novartis International AG, and Pfizer Inc. Backed with competitive intelligence and benchmarking, our research reports on the post-traumatic stress disorder therapeutics market are designed to provide entry support, customer profile and M&As as well as go-to-market strategy support.
Register for a free trial today and gain instant access to 17,000+ market research reports.
Technavio's SUBSCRIPTION platform
Post-traumatic Stress Disorder Therapeutics Market 2020-2024: Key Highlights
- CAGR of the market during the forecast period 2020-2024
- Detailed information on factors that will assist post-traumatic stress disorder therapeutics market growth during the next five years
- Estimation of the post-traumatic stress disorder therapeutics market size and its contribution to the parent market
- Predictions on upcoming trends and changes in consumer behavior
- The growth of the post-traumatic stress disorder therapeutics market
- Analysis of the market's competitive landscape and detailed information on vendors
- Comprehensive details of factors that will challenge the growth of post-traumatic stress disorder therapeutics market vendors
Table Of Contents:
Executive Summary
Market Landscape
- Market ecosystem
Market Sizing
- Market definition
- Market segment analysis
- Market size 2019
- Market outlook: Forecast for 2019 2024
Five Forces Analysis
- Five Forces Summary
- Bargaining power of buyers
- Bargaining power of suppliers
- Threat of new entrants
- Threat of substitutes
- Threat of rivalry
- Market condition
Market Segmentation by Product
- Market segments
- Comparison by Product placement
- Antidepressants Market size and forecast 2019-2024
- Anxiolytics Market size and forecast 2019-2024
- Other PTSD therapeutics Market size and forecast 2019-2024
- Market opportunity by Product
Customer Landscape
Geographic Landscape
- Geographic segmentation
- Geographic comparison
- North America Market size and forecast 2019-2024
- APAC Market size and forecast 2019-2024
- Europe Market size and forecast 2019-2024
- South America Market size and forecast 2019-2024
- MEA Market size and forecast 2019-2024
- Key leading countries
- Market opportunity by geography
Market Drivers
Market Challenges
Market Trends
Vendor Landscape
- Vendor landscape
- Landscape disruption
- Competitive landscape
Vendor Analysis
- Vendors covered
- Market positioning of vendors
- AstraZeneca Plc
- Azevan Pharmaceuticals Inc.
- Bionomics Ltd.
- Eli Lilly and Co.
- GlaxoSmithKline Plc
- H. Lundbeck AS
- Mylan NV
- Neurocrine Biosciences Inc.
- Novartis International AG
- Pfizer Inc.
Appendix
- Scope of the report
- Currency conversion rates for US$
- Research methodology
- List of abbreviations
About Us
Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200525005262/en/
Contacts:
Technavio Research
Jesse Maida
Media Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: media@technavio.com
Website: www.technavio.com/
